Adalvo is pleased to announce the successful EU DCP Submission for Ivermectin 10mg/g topical cream.
Our Ivermectin cream is being developed in collaboration with one of our strategic partners, based on the reference brand Soolantra, Galderma. The product is used on the skin to treat pimples and spots found with rosacea.
According to IQVIA, the INN with strength 1%(10mg/g) generated approximately $214mn in global sales in 2022.
With our clearly defined product pathway, we believe Adalvo will be amongst the first wave of filers, and will be ready to launch on Day-1 in all major markets.
As a company committed to our dermatology portfolio, we offer an array of dossiers and aim to assist our partners in overcoming any challenges that may arise with these mature products.
Our dermatology products include:
- Adapalene Gel
- Adapalene + Benzoyl Peroxide Gel
- Tacrolimus Ointment
- Dimetindene Gel
Partner up now!
At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
margarida.neves@adalvo.com – Brazil
marta.puig@adalvo.com - LATAM (exc. Brazil) & South Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
arni.baldursson@adalvo.com - Head of Global BD&L
Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.